Supplements

Gut microbiota-driven metabolic reprogramming, including accumulation of toxic aromatic amino acid catabolites, is a key contributor to Parkinson's disease with REM sleep behavior disorder and idiopathic RBD.

This study found that Parkinson's disease patients with RBD exhibit distinctive metabolic disturbances, including accumulation of gut microbiota-derived toxic aromatic amino acid catabolites, which were also observed in idiopathic RBD patients. Gut microbial dysbiosis in these groups drives a functional shift away from dietary fiber fermentation toward enhanced degradation of protein, aromatic amino acids, glycine, and intestinal mucin glycans, associated with exacerbated oxidative stress, neuroinflammation, and accelerated pathological progression.

1 min read•Updated Jul 7, 2026•0 RCTs•View structured evidence →
Evidence Score32/100
Human RCT☆☆☆☆☆
Meta-analysis☆☆☆☆☆
Mechanism☆☆☆☆☆
Safety☆☆☆☆☆
Confidencelow

This article is automatically generated from the structured evidence profile behind the claim above. Scores reflect the quality and quantity of available research, not clinical advice.

Gut microbiota-driven metabolic reprogramming, including accumulation of toxic aromatic amino acid catabolites, is a key contributor to Parkinson's disease with REM sleep behavior disorder and idiopathic RBD. The current body of evidence comprises 1 study. EvidenceHub rates the overall confidence at 32/100 (low).

The Claim

Gut microbiota-driven metabolic reprogramming, including accumulation of toxic aromatic amino acid catabolites, is a key contributor to Parkinson's disease with REM sleep behavior disorder and idiopathic RBD.

This conclusion is most relevant to: Parkinson's disease patients with RBD (RBD-PD), idiopathic RBD (iRBD) patients, and other PD subtypes.

What the Research Shows

The conclusion draws on 1 linked study. Highlights from the cited literature:

  • ▸Distinct metabolomic and proteomic signatures in Parkinson's disease patients with REM sleep behavior disorder. (Signal transduction and targeted therapy, 2026) —

How It Works

The proposed biological pathway:

  • ▸Gut microbial dysbiosis reduces dietary fiber fermentation
  • ▸Enhanced degradation of protein, aromatic amino acids, glycine, and intestinal mucin glycans by gut microbiota
  • ▸Accumulation of toxic aromatic amino acid catabolites in plasma
  • ▸Exacerbated oxidative stress, neuroinflammation, and accelerated pathological progression in RBD-PD and iRBD

Who Might Benefit

Evidence fit by population:

  • ▸Parkinson's disease patients with RBD (RBD-PD), idiopathic RBD (iRBD) patients, and other PD subtypes

Limitations & Caveats

Important context when interpreting this evidence:

  • ▸Abstract does not specify sample size or statistical effect sizes for the observed differences
  • ▸Causal relationships between gut microbiota changes and disease progression cannot be established from observational multiomic profiling alone
  • ▸Findings may not generalize to all PD subtypes or populations outside the study cohort

References

  1. 1.Shao Y, Wang J, Liu Y, Ni Y, Liu Z, Li Y, Jia Q, Li Q, Wang X, Li T, Liu M, Zhang S, Guo Y, Guo X, Wang D, Liu Y, Liu C, Cai H, Ning Y, Zhang J, Xu G, Le W. “Distinct metabolomic and proteomic signatures in Parkinson's disease patients with REM sleep behavior disorder..” Signal transduction and targeted therapy, 2026. PMID: 41912482 DOI: 10.1038/s41392-026-02613-8
Disclaimer: This article is auto-generated from structured research data for educational purposes only and is not medical advice. Evidence scores reflect the quality and quantity of available research, not clinical recommendations. Always consult a healthcare professional before starting any supplement or intervention.